Expertise in
11
conditions

Dr. Christopher J. Hoimes

Hematology Oncology | Internal Medicine
Private Diagnostic Clinic PLLC
20 Duke Medicine Cir, Clinic 5 Cancer Center, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
Private Diagnostic Clinic PLLC
20 Duke Medicine Cir, Clinic 5 Cancer Center, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Hoimes is an Internal Medicine provider in Durham, North Carolina. Dr. Hoimes is highly rated in 11 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Orchiectomy. Dr. Hoimes is currently accepting new patients.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Internal Medicine
Licenses
Internal Medicine in OH
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS

Locations

Private Diagnostic Clinic PLLC
20 Duke Medicine Cir, Clinic 5 Cancer Center, Durham, NC 27710
Other Locations
Private Diagnostic Clinic PLLC
2351 Erwin Rd, Durham, NC 27705
Duke Health Integrated Practice Inc
2301 Erwin Rd, Durham, NC 27705

Additional Areas of Focus

Dr. Hoimes has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Renal Cell Carcinoma (RCC)
Choriocarcinoma
Testicular Yolk Sac Tumor
Prostate Cancer
Bladder Cancer
Testicular Cancer
Urothelial Cancer
Chromophobe Renal Cell Carcinoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
Enrollment Status: Recruiting
Publish Date: August 09, 2024
Intervention Type: Biological
Study Drugs: Bacillus of Calmette-Guerin, ALT-803
Study Phase: Phase 1/Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Enrollment Status: Terminated
Publish Date: August 03, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

67 Total Publications

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.
Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.
Journal: JAAD case reports
Published: March 27, 2025
Similar Doctors
Expertise in
37
conditions
Dr. Nigel S. Key
Hematology Oncology | Hematology
Expertise in
37
conditions
Dr. Nigel S. Key
Hematology Oncology | Hematology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 mi)
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Nigel Key is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Key is highly rated in 37 conditions, according to our data. Their top areas of expertise are Hemophilia B, Hemophilia A, Blood Clots, Sickle Cell Disease, and Hip Replacement. Dr. Key is currently accepting new patients.

Expertise in
17
conditions
Dr. David M. Ashley
Hematology Oncology | Hematology | Oncology
Expertise in
17
conditions
Dr. David M. Ashley
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ashley is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Ashley is highly rated in 17 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. Dr. Ashley is currently accepting new patients.

Expertise in
9
conditions
Dr. Jane A. Little
Hematology Oncology | Oncology | Hematology
Expertise in
9
conditions
Dr. Jane A. Little
Hematology Oncology | Oncology | Hematology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 mi)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Little is a Hematologist Oncology specialist and an Oncologist in Chapel Hill, North Carolina. Dr. Little is highly rated in 9 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Little is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoimes's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile